Joanne E. Tomassini

Aug 31, 2023 | nature.com | Spyros Chalkias |Joanne E. Tomassini |Xing Chen |Xiaoying Shen |Darin Edwards |Stephen Walsh

AbstractThis ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Two groups of adults who previously received mRNA-1273 as primary vaccination series and booster doses were enrolled in a sequential, nonrandomized manner and received single-second boosters of mRNA-1273 (n = 376) or bivalent mRNA-1273.222 (n = 511).

Aug 23, 2023 | nature.com | Stephen Walsh |Joanne E. Tomassini |Xing Chen |Darin Edwards

AbstractWe previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received the mRNA-1273 primary series (100-µg) and mRNA-1273 first booster (50-µg) dose.